How Semax/Selank Fits Into Focus & Energy Stack Research

How Semax/Selank fits into Focus & Energy stack research is by treating the stack as a second combination on top of the first, Semax plus Selank, plus NAD+ 100mg, with all of the same separation problems, for three components instead of two, and by asking whether a stack study can separate Semax/Selank from NAD+, or whether it can only report a stack outcome, with no component attribution at all.

In the Focus & Energy Stack, Semax/Selank is sold together with NAD+ 100mg. For an overview of the combined film, see Semax/Selank buccal strips research.

This article on how Semax/Selank fits into Focus & Energy stack research is presented as research material only. It does not diagnose, treat, cure, or prevent any disease, does not recommend use in people, and does not present buccal strips as an approved drug or supplement for human consumption.

What the Focus & Energy Stack is, as a research object

On the product page, the Focus & Energy Stack is presented as Semax/Selank Buccal Strips plus NAD+ Buccal Strips 100mg, in a bundle described as 2 boxes and 50 strips, at $292.00, was $324.00, with a subscribe breakdown of Semax/Selank at $169.20, was $235.00, and NAD+ 100mg at $64.08, was $89.00. Those figures are product presentation, not research data, and they are listed here only to define the stack that is being studied.

As a research object, that stack is not one product. It is two products, with different peptides, different forms, and different bodies of research, presented together. Semax/Selank is itself a two-peptide combination, with neurotrophic, monoamine, GABAergic, enkephalin, and neuroimmune signaling, as covered in the signalling comparison article. NAD+ is a coenzyme precursor, with a different body of research, centred on cellular energy, sirtuin signaling, and NAD+ levels in models, not on neuropeptide signaling.

A stack study that reports a general outcome, such as a model cognitive or energy outcome, and attributes it to the stack, has reported a stack outcome. It has not attributed that outcome to Semax/Selank, to NAD+, or to their interaction, unless its design separates them.

Why a three-component stack is harder than a two-peptide combination

A two-peptide combination, as covered in the combination design article, needs four arms for a full factorial design: vehicle, Semax, Selank, and Semax plus Selank. A three-component stack, if it is treated as three components, Semax, Selank, and NAD+, needs eight arms for a full factorial design: vehicle, each single, each pair, and all three together.

Most stack studies do not run eight arms, and most product presentations do not claim to. They run stack versus vehicle, or stack versus one component, and report a stack outcome. That is a legitimate, limited design, read correctly, but it cannot support a component claim. A stack versus vehicle study cannot say Semax/Selank contributed, or NAD+ contributed, or that they interacted. It can only say the stack, as given, differed from vehicle, in that model, for that outcome.

A stack versus one component study, for example stack versus Semax/Selank alone, can ask whether adding NAD+ changes a Semax/Selank outcome, but it cannot ask whether NAD+ alone changes that outcome, or whether Semax, Selank, and NAD+ interact, because it lacks the other arms. That design is a partial factorial for a stack, and its claims must be partial too.

What a stack study would need to report, to be readable

A readable stack study would report, at minimum, the stack composition explicitly, including Semax content, Selank content, and NAD+ content, per film and per box, for each product in the stack, and the route and form for each product, buccal film for both products in this stack, not mixed routes, unless mixed routes are stated and controlled for.

It would also report the design explicitly: which arms were run, which components were separated, and which were not, and what the stack outcome was, for each arm, on the same measures and at the same time points. Without that arm list, a reader cannot tell whether a stack result is a stack result, a Semax/Selank result, a NAD+ result, or a total-dose result, because stack, components, and total dose all change together in a stack versus vehicle design.

That arm list is especially important here because NAD+ and Semax/Selank have different bodies of research, and different proposed mechanisms. A stack outcome that is positive on a general model could be driven by NAD+ cellular energy measures, by Semax neurotrophic measures, by Selank GABAergic measures, or by none of them, and only system-specific measures, for each component, in the same study, could separate them, as covered in the signaling article.

Performance Stack: the other stack, and why it is not a separate article here

On the product page, Semax/Selank also appears in the Performance Stack, with CJC-1295/Ipamorelin and BPC-157/TB-500, in a bundle described as 3 boxes and 70 strips, at $489.00, was $575.00. That stack is mentioned here, not as a separate article, because its research problem is the same as the Focus & Energy problem, with more components, and therefore even more arms, and even less component attribution, unless a full factorial design is run, which product presentations do not do.

Writing a separate Performance Stack article, with the same design argument, would duplicate this article with different product names. Mentioning it here, as a second example of the same stack problem, avoids that duplication, and keeps the focus on the product, not on stack inflation.

A reader who needs Performance Stack design in detail should apply the same rule from this article: a stack outcome belongs to the stack, unless its design separates its components, and a stack with more components needs more arms, not fewer, to support a component claim.

External Evidence

Semax literature, as reviewed for this article, is centred on ACTH-fragment biology, BDNF and neurotrophic signalling in animal models, monoamine modulation, and Russian intranasal clinical work, with limited independent Western replication, used here as the Semax/Selank baseline, not as stack evidence.

Selank literature, as reviewed for this article, is centred on tuftsin-derived biology, GABAergic modulation, enkephalin-degrading enzyme inhibition, and small Russian human intranasal anxiety work, with limited Western replication, used here as the Semax/Selank baseline, not as stack evidence.

NAD+ literature, as reviewed for this article, is centred on cellular NAD+ levels, sirtuin signalling, and energy metabolism in models, with different measures from neuropeptide signalling, and is cited here only to show that NAD+ is a different system from Semax and Selank, not as evidence that a Semax/Selank plus NAD+ stack changes any outcome in people.

What Focus & Energy Stack Research Can Establish

• Whether a Semax/Selank plus NAD+ stack, as given, differs from vehicle, or from a single component, on a given outcome, in a given model, with the arms actually run.
• Whether a stack study design separates Semax/Selank from NAD+, or confuses them, for that outcome, in that model.
• Whether a stack outcome tracks with Semax-related measures, Selank-related measures, NAD+-related measures, or none of them, where those measures are reported in the same study.
• Whether a Performance Stack, with more components, has the same design problem, with even less component attribution, unless more arms are run.

What Focus & Energy Stack Research Does Not Establish

• That a stack outcome belongs to Semax/Selank, to NAD+, to Semax alone, to Selank alone, or to an interaction, without a factorial design that separates those components.
• That a stack improves focus, energy, attention, calm, memory, or cognitive performance in people, for any component or for the stack.
• That a Semax/Selank result, a NAD+ result, or a single-peptide result is a stack result, without stack data.
• That a stack that is positive on one measure is positive on another measure, or that a stack benefit in a model is a benefit in people.

Final Perspective

Stacks are where product presentation and research design diverge most sharply. A stack, presented as a bundle, feels like a single product, with a single benefit, and a single price. In research, a stack is a combination of combinations, with a design problem that multiplies with each component, and with component claims that shrink as the stack grows, unless the design grows with it.

That is why this article does not present the Focus & Energy Stack as a better Semax/Selank, or as a better NAD+, or as a new product with its own mechanism. It presents it as a stack, with a stack design, and a stack limit, which is the only honest way to present a stack in a research-only article.

For the limits that remain, even after film, delivery, signalling, combination, and stack questions are answered, see how Semax/Selank buccal strips research limits are interpreted in peptide research.

Related product: Semax/Selank Buccal Strips, Semax 500 mcg and Selank 500 mcg per film, 20 count, research material. Details on the product page.